HLS ASX: Pathology group Healius is restructuring management and cutting costs in its largest business, as UBS presses on with strategic review

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 90%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.

Two top executives in the group’s Queensland pathology business QML have departed in the restructure outlined in an internal email on March 27 from the boss of the Healius Pathology division, Jan Van Rooyen.

Healius, formerly known as Primary Health Care, replaced its chief executive, Maxine Jaquet, in early March after just 12 months in the job following a profit plunge and $2 billion in sharemarket value disappearing. A revival in the financial performance of the pathology division is crucial for Healius. Mr Van Rooyen was hired to run the division after having been the CEO of AMPATH in South Africa for almost 20 years, which he built into a national business after integrating several smaller operations.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

 /  🏆 2. in NL
 

Bedankt voor uw reactie. Uw reactie wordt na beoordeling gepubliceerd.

Nederland Laatste Nieuws, Nederland Headlines